2020 International Meeting on the Molecular Biology of Hepatitis B Viruses

2020年乙型肝炎病毒分子生物学国际会议

• 批准号: 9992951
• 负责人: Ourania M. Andrisani
• 金额: $ 0.9万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-09 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9992951
• 关键词: Achievement; Address; Anabolism; Animal Model; Animals; Antiviral Agents; Antiviral Therapy; Asia; Australia; Award; Basic Science; Biochemistry; Biology; Biomedical Research; Canada; Cancer Etiology; Cell model; Cells; Cellular biology; Chronic; Chronic Hepatitis B; Communities; Complement; Country; Data; Development; Disease; Education; Effectiveness; Ensure; Europe; Financial Support; Foundations; Funding; Gene Expression; Genetic Transcription; Goals; Hepatitis B; Hepatitis B Vaccines; Hepatitis B Virus; Hepatitis Delta Virus; Hepatocyte; Human; Immunology; International; Light; Link; Liver; Liver diseases; Location; Malignant neoplasm of liver; Methods; Mission; Molecular; Molecular Biology; National Cancer Institute; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; North America; Oral; Organoids; Pathogenesis; Postdoctoral Fellow; Primary carcinoma of the liver cells; Public Health; RNA Editing; Reagent; Regulatory Element; Reproducibility; Research; Research Personnel; Resources; Risk; Scientist; Senior Scientist; Site; Standardization; Technology; Time; Training; Travel; Underrepresented Minority; United States National Institutes of Health; Universities; Virus; Virus Diseases; Virus Shedding; career; cost; drug development; effective therapy; gene therapy; global health; graduate student; improved; interest; liver development; meetings; minority investigator; mortality; new technology; novel strategies; novel therapeutic intervention; pathogen; posters; prevent; programs; prophylactic; protein expression; single cell sequencing; social; success; therapy development; tool; vector; virology; virus development; virus related cancer

ABSTRACT/SUMMARY Hepatitis B virus (HBV) infection is a significant global public health problem, with over 290 million people worldwide being chronically infected. Significantly, chronic HBV infection is associated with increased risk for development of hepatocellular carcinoma (HCC), the 2nd leading cause of cancer-related mortality worldwide. Despite the effectiveness of the prophylactic HBV vaccine, there is no cure for chronic HBV infection or the resultant liver cancer. There is compelling need to discover new therapeutic strategies to cure chronic HBV infection and HCC pathogenesis. Thus, the global HBV scientific community must continue to make directed strides towards understanding key, unanswered aspects of HBV biosynthesis and disease pathogenesis. The annual meeting on the Molecular Biology of Hepatitis B Viruses is the only forum that brings together the international community of scientists who study mechanisms of biosynthesis and pathogenesis by HBV and and its closely associated hepatitis delta virus (HDV). This International meeting on Hepatitis B Viruses has been held yearly since 1985, alternating at sites in North America, Europe, Asia and Australia. In 2020, the meeting will be held in Toronto, Canada. The success and achievements of the HBV field relies on the contributions of not only the established investigators but more importantly, on early career researchers (ECRs) that have/are deciding to enter the field, bringing with them new technology and concepts. Accordingly, the Specific Aim of this R13 application is: to promote and maximize attendance and participation of early career researchers/ECRs (graduate students & postdoctoral fellows) at the 2020 International HBV Meeting. The 2020 meeting will provide the stage for scientific exchange and dissemination of the latest research results that could influence new therapeutic strategies for HBV and HDV infections. It is estimated that 500-600 delegates will attend the 2020 meeting. The organization of the meeting will consist of 8 oral scientific sessions and 5 poster sessions including for the first time, e-poster presentations, as a training stage for early career scientists. In support of the goal of the global scientific strategy to cure HBV, keynote speakers will present new perspectives and technologies, and discuss standards that can be applied to advance the HBV field. To improve scientific interactions and scientific exchange, social gatherings are organized at the end of each meeting day. Significantly, since 2005, the International HBV meeting enjoys the continuing support from the Hepatitis B Foundation, minimizing the meeting costs, and publicizing the meeting to universities with large numbers of underrepresented minorities. To enable participation of early career trainees and underrepresented minority investigators, support from the National Institutes of Health to help defray the travel costs is requested. This funding will be used to ensure attendance and presentations by early career researchers, particularly from countries with lesser developed research capacity, as well as underrepresented minority investigators.

摘要/摘要 肝炎病毒（HBV）感染是一个重大的全球公共卫生问题，有超过2.9亿人 全世界被长期感染。值得注意的是，慢性HBV感染与增加的风险有关 肝细胞癌（HCC）的发展，这是全球与癌症相关死亡率的第二大主要原因。 尽管预防性HBV疫苗具有有效性，但仍无法治愈慢性HBV感染或 由此导致的肝癌。迫切需要发现新的治疗策略来治愈慢性HBV 感染和HCC发病机理。因此，全球HBV科学界必须继续指导 迈向理解HBV生物合成和疾病发病机理的钥匙，未得到解答的方面。 关于乙型肝炎病毒分子生物学的年度会议是唯一汇集的论坛 HBV和 以及与Delta病毒（HDV）密切相关的肝炎。这次有关乙型肝炎病毒的国际会议一直是 自1985年以来每年举行，在北美，欧洲，亚洲和澳大利亚的地点交替。在2020年，会议 将在加拿大多伦多举行。 HBV领域的成功和成就取决于 不仅是已建立的研究人员，更重要的是，关于早期职业研究人员（ECR） 决定进入该领域，并带来新技术和概念。因此，具体目的 此R13应用程序是：促进和最大化早期职业研究人员/ECRS的出勤率和参与 （研究生和博士后研究员）在2020年国际HBV会议上。 2020年的会议将为科学交流和传播最新研究提供阶段 可能影响HBV和HDV感染的新治疗策略的结果。据估计500-600 代表将参加2020年会议。会议的组织将包括8个口头科学会议 和5次海报会议，包括首次，电子寄主演讲，作为早期职业的培训阶段 科学家。为了支持全球科学战略治疗HBV的目标，主题演讲者将提出新的 观点和技术，并讨论可用于推进HBV领域的标准。改进 科学互动和科学交流，在每个会议结束时组织社交聚会。 值得注意的是，自2005年以来，国际HBV会议享有丙型肝炎的持续支持 基金会，最大程度地减少会议费用，并将会议宣传给有大量的大学 代表性不足的少数民族。 为了使早期职业学员和代表性不足的少数族裔调查员参与 我们要求支付旅行成本的国家卫生研究院。这笔资金将用于确保 早期职业研究人员的出席和演讲，特别是来自发展较小的国家 研究能力以及代表性不足的少数群体研究人员。